在诊断结直肠多体后,阿司匹林的目标试验仿真
Louise Emilsson1,2,3,4, Mingyang Song5,6,7, Jonas F Ludvigsson8,9,10
1Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. louise.emilsson@medisin.uio.no.
European journal of epidemiology
|June 15, 2023
概括
片切除后使用阿司匹林可能会在10年内将结直肠癌 (CRC) 发病率降低2%. 然而,它没有影响CRC死亡率,并且与所有原因死亡率增加4%有关.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 预防医学 预防医学
背景情况:
- 关于阿司匹林对结直肠癌 (CRC) 的化学保护作用,存在相互矛盾的证据.
- 之前的研究对阿司匹林在CRC预防中的作用产生了不一致的结果.
研究的目的:
- 模拟一项临床试验,研究在多片被去除后,在个体中开始服用阿司匹林.
- 评估阿司匹林对结直肠癌发病率,死亡率和全因死亡率的影响.
主要方法:
- 分析了瑞典 (年龄在45-79岁之间) 发生的息肉个体的全国性队列.
- 逆概率权重被用来模拟一个目标试验的阿司匹林启动在两个多检测的几年内.
- 结果包括CRC发病率,CRC死亡率和所有原因死亡率,记录到2019年.
主要成果:
- 在31,633名符合条件的个体中,5%的人开始服用阿司匹林后诊断.
- 阿司匹林发起者显示,10年累计CRC发病率为6%,而非发起者为8% (HR:0.88).
- 在不同组中,CRC死亡率相似 (HR:0.90),而在阿司匹林发起者中,全因死亡率更高 (HR:1.18).
结论:
- 片切除后开始服用阿司匹林与10年CRC累计发病率的适度降低2%有关.
- 阿司匹林没有显著改变结肠直肠癌死亡率.
- 在开始服用阿司匹林的人群中,观察到所有原因死亡的风险差异增加了4%.
相关概念视频
01:26Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
114
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
114
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
160
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
160